Understand the study question
EMA information for Wegovy describes a trial in which participants continued the medicine or received placebo after an initial shared period. Their subsequent weight trajectories differed. This documents a trial setting, not an instruction to stop, continue or restart medication yourself.
Prepare next steps with the team
Ask why stopping might be considered, which objectives will be monitored and how other medicines will be managed. Discuss food organisation, activity compatible with health and difficulties that may return. Keep plans adaptable; excessive rigidity can be hard to maintain.
Avoid a personal-failure narrative
Weight change after a treatment change should not be framed as a moral fault. Bring observations to follow-up and examine options with the team. We offer no supplement substitution programme, tapering schedule or guarantee of maintained results.
EXAMPLE / HOW TO USE IT
Keep three questions
What is the reason for the change? Which indicators will we follow beyond weight? When should I contact you if difficulties return? Write agreed answers and keep the care team’s contact details in your own records.
Read the figure text
Understand the study question: EMA information for Wegovy describes a trial in which participants continued the medicine or received placebo after an initial shared period. · Prepare next steps with the team: Ask why stopping might be considered, which objectives will be monitored and how other medicines will be managed. · Avoid a personal-failure narrative: Weight change after a treatment change should not be framed as a moral fault.
Keep this checklist
- Discuss next steps from the start.
- Clarify the reason for a change.
- Define follow-up elements.
- Keep contact with the care team.
Sources and limitations
- EMA — Wegovy indications and medicine information
- HAS — care pathway for overweight and obesity (French)
References consulted for this edition. Studies and documents retain their actual years. Educational examples and documentary procedures, not personal product trials.
